GNI GROUP LTD.
Contact Us
About Us
About Us TOP
Message
Business Model
Main Products
Management Policy
Company Overview
Board of Directors
Main Group Structure
Office
Corporate governance
R&D
R&D TOP
Pipeline
Discovery Research
Research publications
Investor Relations
Investor Relations TOP
IR News
Information
IR Materials
IR Calendar
IR Email Subscription
Electronic Public Notices
Sustainability/ESG
Sustainability/ESG TOP
Sustainability Initiatives
ESG Data
Contact Us
Site Map
Privacy Policy
Terms of Use
ソーシャルメディアポリシー
2011's Information
トップページ
Information
2011年
All
2025
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2011/12/28
Notice for Large Volume Exercise of the 35th Round of Stock Options
2011/12/19
Notice for Large Volume Exercise of the 35th Round of Stock Options
2011/12/16
Shanghai Genomics received research subsidy for F647 development from Shanghai Pudong New Area Government
2011/12/14
Notice for Large Volume Exercise of the 35th Round of Stock Options
2011/12/12
Notice for Large Volume Exercise of the 35th Round of Stock Options
2011/12/07
Notice of Payment for the 35th Round of Stock Options
2011/11/21
GNI Announces Third-Party Allotment and the Issuance of the 35th Round of Stock Options with Moving Strike
2011/10/31
SAPA-President Forum
2011/09/22
China SFDA Approves F647/Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis
2011/09/15
World Orphan Drug Congress
1
2
3
>